ABO (hydrochloride)
目录号 : GC42677
A modulator of annexin A7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ABO is a modulator of annexin A7. It binds to Thr286 and inhibits phosphorylation of annexin A7 at threonine, but not serine or tyrosine, residues in human umbilical vein endothelial cells (HUVECs). ABO enhances the interaction between annexin A7 and the EF-hand protein GCA, decreases GCA phosphorylation as well as intracellular calcium concentration, and promotes autophagy in COS-7 cells. It also decreases phosphorylation of microtubule-associated protein 1 light chain (LC3) in HUVECs and suppresses oxidized low-density lipoprotein-induced increases in phosphatidylcholine-specific phospholipase C (PC-PLC) expression in vascular endothelial cells (VECs). In vivo, ABO (50 or 100 mg/kg per day) decreases PC-PLC levels, enhances autophagy, and reduces apoptosis, lipid deposition, and atherosclerotic plaque area in the aortic endothelium of apoE-/- mice fed a Western diet.
| Cas No. | SDF | ||
| Canonical SMILES | NC1=CC=C(OCC(CO)N2)C2=C1.Cl.Cl | ||
| 分子式 | C9H12N2O2•2HCl | 分子量 | 253.1 |
| 溶解度 | DMF: 2 mg/ml,DMSO: 2 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.951 mL | 19.755 mL | 39.5101 mL |
| 5 mM | 0.7902 mL | 3.951 mL | 7.902 mL |
| 10 mM | 0.3951 mL | 1.9755 mL | 3.951 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Isolated V-Lesion in an ABO-Incompatible Kidney Transplant Recipient Receiving Rituximab
Exp Clin Transplant 2019 Oct;17(5):678-680.PMID:29137592DOI:10.6002/ect.2017.0062.
We report an ABO-incompatible kidney transplant performed on a 69-year-old female patient, whose donor was her 69-year-old husband. The patient received an immunosuppressive protocol using rituximab without splenectomy. Renal biopsy was done on posttransplant day 8 due to poor early graft function, and an isolated v-lesion was found, which responded to steroid pulse therapy and gusperimus hydrochloride administration. Our results indicate that isolated v-lesions can occur in ABO-incompatible kidney transplant recipients receiving rituximab and that this finding should be treated as acute rejection. To our knowledge, this is the first report of an isolated v-lesion in an ABO-incompatible kidney transplant recipient who had been administered rituximab.
Procainamide-induced hemolytic anemia
Transfusion 1978 Mar-Apr;18(2):224-7.PMID:417435DOI:10.1046/j.1537-2995.1978.18278160589.x.
The paper reports a case of hemolytic anemia induced by procainamide hydrochloride treatment. Decreases in hemoglobin concentration are correlated with 11 months of procainamide treatment along with a marked increase in hemoglobin following cessation of the drug. The patient exhibited no symptoms suggestive of drug-induced Lupus Erythematosus that has been frequently reported as a sequela of procainamide therapy. Direct antiglobulin tests were consistently positive throughout the clinical course, and an ether-eluate prepared from the patient's red blood cells showed panagglutinability. The antibody in the eluate reacted with Rhnull, D--, LW negative, and U negative red blood cells without addition of procainamide or pretreatment of red blood cells with the drug. It is noted that this antibody reacts similarly to the antibody produced as a consequence of alpha-methyl-dopa therapy.
Effects of 1% cyclopentolate hydrochloride on anterior segment parameters obtained with Pentacam in young adults
Arq Bras Oftalmol 2014 Aug;77(4):228-32.PMID:25410174DOI:10.5935/0004-2749.20140059.
Purpose: To investigate the effects of topically applied 1% cyclopentolate hydrochloride on anterior segment parameters obtained with a Pentacam rotating Scheimpflug camera in healthy young adults. Methods: Anterior segment analyses of 25 eyes from 25 young adults (Group 1), before and after 45 min of 1% cyclopentolate hydrochloride application, were performed. For a control group (cycloplegia-free, Group 2), 24 eyes of 24 age- and sex-matched healthy cases were evaluated twice at 45 min intervals. The results obtained from the groups were compared statistically. Results: The mean ages of the groups were 23.04 ± 3.42 (range, 18-29) and 22.4 ± 2.05 (range, 18-27) years for Groups 1 and 2, respectively (p=0.259). In Group 1, measurements between the two analyses were significantly different for the values of anterior chamber depth (ACD), anterior chamber angle (ACA), and anterior chamber volume (ACV) (p<0.05), whereas no statistical difference was found for the central corneal thickness (CCT) and keratometry (K1, K2) measurements. In Group 2, none of these parameters were statistically different between the two analyses. Conclusions: Topically applied 1% cyclopentolate hydrochloride caused an increase in the ACD and ACV values, and a decrease in the ACA value. However, it had no significant effect on the CCT and keratometry measurements. It is important to consider these effects when using the Pentacam device on young adults with cycloplegia and when applying it for various reasons.
In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates
Int J Pharm 2015 Aug 1;491(1-2):8-16.PMID:26051543DOI:10.1016/j.ijpharm.2015.06.002.
The use of solid oral dosage forms is typically favored with regard to stability and ease of administration. The aim of this study was to investigate whether cyclodextrins (CD) or ion exchange resins (IER) could be used to taste-mask cetirizine HCl when formulated in a freeze-dried oral formulation. The oral lyophilisates were produced using the Zydis(®) technology that offer the opportunity to produce the dosage form directly in the aluminum laminate blister packs. This study confirmed that a pre-formed resinate of cetirizine HCl and various cyclodextrins can be successfully incorporated into the Zydis(®) oral lyophilisate. A chemically stable product with acceptable release profile was obtained in the case of cyclodextrin. This study has also demonstrated that the Insent(®) taste sensing system is a useful technique for predicting the taste-masking potential of Zydis(®) formulations. The electronic taste sensing system (e-tongue) data can be used to provide guidance on the selection of taste-masked formulations. Principal component analysis (PCA) of sensor data by plotting the PCA scores revealed the effects of used taste-masking techniques on the e-tongue sensors, indicating the successful taste improvement. The PCA plot of the taste sensor data revealed larger distances between the non-taste-masked sample and the CD- and IER-loaded samples, and the shift toward the drug-free formulations and excipient signals indicates a modification of the product taste. The human taste trial confirms the acceptability of the selected promising formulations. The taste evaluation results showed that an effectively taste-masked formulation has been achieved using β-cyclodextrin and cherry/sucralose flavor system with over 80% of volunteers finding the tablet to be acceptable.
Facile Fabrication of Cellulose Nanofibrils/Chitosan Beads as the Potential pH-Sensitive Drug Carriers
Polymers (Basel) 2022 Jun 4;14(11):2286.PMID:35683958DOI:10.3390/polym14112286.
It is highly desirable to develop a safe, highly efficient, and biodegradable drug carrier with an enhanced drug transport efficiency. Cellulose nanofibrils (CNF) and chitosan (CS) composite hydrogels are promising candidate carriers with biological compatibility and non-cytotoxicity. Herein, the CNF/CS composite beads were prepared by dissolving cellulose and CS in LiBr molten salt hydrate and regenerating in ethanol. This preparation method is facile and efficient, and the obtained porous CNF/CS beads with the weight ratio of 8:2 exhibited a large specific surface area, uniform micro-nano-sized pores, strong mechanical property, and water absorption-resistance. Moreover, these beads as drug (tetracycline hydrochloride, TH) carriers showed a higher encapsulation efficiency (47.4%) at the TH concentration of 5 mg/mL in 24 h, and a higher drug loading rate (12.0%) than pure CNF and other CNF/CS beads prepared with different ratios. In addition, the TH releasing behavior of CNF/CS (8:2) beads fitted well into the zero-order, first-order, and Higuchi models under an acid condition, indicating that the drug release of these pH-sensitive beads was mainly affected by drug concentration under an acid condition. Therefore, these CNF/CS beads have great potential to be used as drug carriers for medical applications.